Omada Health's Enhanced GLP-1 Care Track Demonstrates Increased Medication Persistence and Weight Loss Outcomes at 12 and 24 Weeks
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada's companion program can help sustain GLP-1 use, delivering on clinical trials' promises
SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, released new data1 demonstrating that Omada's GLP-1 companion program significantly improved persistence rates for GLP-1 medications. Evidence suggests that persistence on a GLP-1 is associated with greater weight loss.2 Omada's analysis found that those who persisted with their GLP-1 medication achieved weight loss results similar to what has been found in controlled research settings.1
Despite a growing body of evidence supporting vast clinical benefits of GLP-1s,3 while results vary widely, one study showed that one-third of people stopped taking their GLP-1 in the first month, and less than half stayed on for more than 12 weeks.4 These data suggest that in the real world, factors like non-persistent medication use mean that many who use GLP-1s for weight management may not see the results reflected in clinical trials.
'While published literature illustrates the incredible potential of GLP-1s, these outcomes are generally limited to those who consistently use their medication long enough to see benefit. In the real world many patients do not receive the necessary support for this to be a reality,' said Sarah Linke, PhD, MPH, Senior Director, Clinical & Translational Research, Omada Health. 'Omada's GLP-1 companion program helps individuals maintain their medication regimen and, in this analysis, helped members achieve clinical trial-level outcomes in real-world settings, which sets the stage for cardiometabolic disease reduction.'
Omada analyzed 1,124 members without diabetes who self-reported GLP-1 use to assess the impact of its Enhanced GLP-1 Care Track on medication persistence through 24 weeks. Self-reported medication initiation and persistence were confirmed using objective pharmacy claims data. Previous real-world studies have demonstrated a wide range in medication persistence rates at 12 weeks (42%4 to 80%5) and 24 weeks (33%6 to 74%5) after starting GLP-1s. In contrast, members included in this analysis of Omada's Enhanced GLP-1 Care Track demonstrated higher persistence rates—94% through 12 weeks and 84% through 24 weeks.1
This analysis also found the average weight loss for Omada members that persisted on their medication through 24 weeks was closely aligned with 24-week outcomes from a recent head-to-head clinical trial7 comparing tirzepatide and semaglutide in a similar population. Whereas Omada members who stopped taking their GLP-1 medication any time before 24 weeks lost an average of 7.4% of their body weight, those who remained on their medication through 24 weeks lost an average of 12.1%—a 64% relative increase.1 Providing the right kind of support to enable members to persist with their GLP-1 medication long enough to see benefits can help them achieve clinical trial-level weight loss outcomes, setting the stage for cardiometabolic disease risk reduction.
Omada's Enhanced GLP-1 Care Track provides targeted resources for members as they move through their GLP-1 use journey. Members in this companion program receive high-touch care team support to help overcome common barriers to persistence – from education around dose titration, common side effects, and mitigation strategies to nutrition guidance and support from Exercise Specialists to combat muscle loss. Members who plan to stop their medication due to access concerns may receive resources that help them understand their options and navigate the larger healthcare ecosystem.
'We are in the fortunate position that more patients are getting access to these transformative medications,' said Wei-Li Shao, President, Omada Health. 'However, with increased access comes the responsibility to ensure GLP-1 use remains cost-effective by supporting sustainable long-term health benefits. We believe these findings highlight the potential of Omada's program to enhance clinical outcomes with improved medication persistence and a focus on engagement in healthy lifestyle behavior changes."
This analysis was conducted through Omada's Insights Lab as part of the ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) initiative, and builds on more than a decade of insights and 29 peer-reviewed publications assessing the efficacy of behavior change programs to improve chronic disease management.
Omada HealthOmada Health is a virtual-first healthcare provider that nurtures lifelong health, one day at a time. Omada care teams implement clinically-validated behavior change protocols for individuals living with diabetes, hypertension, prediabetes, and musculoskeletal issues. With more than a decade of experience and data, and 29 peer-reviewed publications that showcase its clinical and economic results, Omada is designed to help improve health outcomes and contain healthcare costs. Omada's scope exceeds 2,000 customers, including health plans, health systems, and employers ranging in size from small businesses to Fortune 500s.
The foundation of Omada's success is a strong, vibrant work culture, which helped earn the company the distinction of becoming an officially certified Great Place to Work®. An industry leader, Omada was the first virtual provider to join the Institute for Healthcare Improvement's Leadership Alliance, reflecting the aim to complement primary care providers for the benefit of members, and affirming its guarantee to every partner: Omada works differently.
ContactsRose Ramsethpress@omadahealth.com
1Chang, H., Devaraj, S. M., Naqvi, J. B., & Linke, S. (2025). GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. GLP-1 Medication Persistence, a Key Component of Weight Loss. Omada Health. https://resourcecenter.omadahealth.com/white-papers/glp-1-medication-persistence-a-key-component-of-weight-loss2Gasoyan, H., Butsch, W. S., Schulte, R., Casacchia, N. J., Le, P., Boyer, C. B., Griebeler, M. L., Burguera, B., & Rothberg, M. B. (2025). Changes in weight and glycemic control following obesity treatment with semaglutide or tirzepatide by discontinuation status. Obesity, 2025, 1-11. https://doi.org/10.1002/oby.243313Xie, Y., Choi, T., & Al-Aly, Z. (2025). Mapping the effectiveness and risks of GLP-1 receptor agonists. Nature, 31, 951–962. https://doi.org/10.1038/s41591-024-03412-w4Blue Health Intelligence®. (2024, May). Real‑world trends in GLP‑1 treatment persistence and prescribing for weight management [PDF]. Blue Cross Blue Shield Association. Retrieved June 16, 2025, from https://www.bcbs.com/dA/46383dfc2d/fileAsset/BHI_Issue_Brief_GLP1_Trends.pdf 5Hankosky, E. R., Karishma, D., Chinthammit, C., Grabner, M., Stockbower, G., He, X., Mojdami, D., Wenziger, C., & Gibble, T. H. (2025). Real-world use and effectiveness of tirzepatide among people without evidence of type 2 diabetes in the United States. Diabetes & Metabolism, 51 (3), 101636. https://doi.org/10.1016/j.diabet.2025.1016366Gleason, P. P., Urick, B. Y.,Marshall, L. Z., Friedlander, N., Qiu, Y., & Leslie, R. S. (2024). Real-world persistence and adherence to glucagon-like peptide-1 receptor agonists among obese commercially insured adults without diabetes. Journal of Managed Care & Specialty Pharmacy, 30 (8), 860-867. https://doi.org/10.18553/jmcp.2024.23332 7Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Valderas, E. G., Das, S., Lee, C. J., Glass, L. C., Senyucel, C., & Dunn, J. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity, NEJM, 2025. https://doi.org/10.1056/NEJMoa2416394Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Hernia Repair Devices Market is Set to Attain Valuation of US$ 6.57 Billion by 2033
Hernia repair devices market is experiencing strong growth momentum driven by rising procedural volumes, technological advancements in mesh and robotic systems, and increasing adoption of minimally invasive techniques across both developed and emerging regions. Chicago, June 25, 2025 (GLOBE NEWSWIRE) -- The global hernia repair devices market was valued at US$ 4.69 billion in 2024 and is projected to reach US$ 6.57 billion by 2033, growing at a CAGR of 4.32% during the forecast period 2025–2033. Global physicians performed nearly 40 million hernia repairs in 2024, according to the International Hernia Society, underscoring an epidemiological load that directly feeds the hernia repair devices market. Abdominal-wall weakness is amplified by rising obesity, rapid urbanization, and strenuous occupations, leading to earlier presentation of inguinal and incisional defects. In the United States alone, procedure volumes climbed above 1.1 million last year, while Asia-Pacific hospitals are quickly closing that gap as ageing populations swell. Improved diagnostic outreach in Brazil, India, and Nigeria lifts latent incidence into surgical theatres, creating a rare consistency in risk-factor universality that is largely unaffected by cultural nuances. Seasoned surgeons at Cleveland Clinic confirm that emergency admissions remain proportional to elective bookings, signaling that supply expansion must run parallel to prevention initiatives to tame hospital bed occupancy. Download Sample Pages: While incidence drives baseline demand, referral patterns set the gradient of device utilization. Private-insurance penetration in Germany and Australia now reimburses outpatient mesh repair, shifting operations from public inpatient wards to ambulatory centers equipped with lighter fixation instruments. Conversely, large government camp programs in Vietnam distribute pre-sterilized polypropylene plugs to district surgeons, creating a two-tiered yet interconnected ecosystem for the hernia repair devices market. Both channels rely on supply-chain resilience; pandemic-era shortages still echo in Mexico, where delayed shipments doubled surgical waitlists last winter. To buffer regional demand shocks, manufacturers are decentralizing production, with new molding facilities announced in Gujarat and North Carolina during 2024. Key Findings In Hernia Repair Devices Market Market Forecast (2033) US$ 6.57 billion CAGR 4.32% Largest Region (2024) North America (51%) By Product Type Hernia Mesh (77%) By Surgery Type Inguinal Hernia (67%) By Procedure Type Open Surgery (77%) Top Drivers Rising hernia prevalence boosts demand for repair devices Aging population increases need for hernia surgical solutions Growing adoption of minimally invasive devices drives market Top Trends Bioabsorbable meshes gain traction for safer hernia repairs Robotic-assisted hernia surgeries enhance precision and recovery speed Lightweight synthetic meshes reduce complications in hernia procedures Top Challenges High costs of advanced hernia devices limit accessibility Post-surgical complications with meshes challenge market trust Stringent regulatory approvals delay hernia device innovations Shift Toward Mesh Implants Dominates Current Surgical Preference Globally Today Modern guidelines from the European Hernia Society unequivocally recommend tension-free mesh placement for most primary abdominal-wall defects, a view echoed by the Americas Hernia Society in its 2024 update. This convergence has triggered brisk expansion of lightweight synthetic meshes, which now represent the majority of consumables shipped to U.S. and Japanese hospitals. Clinicians favor macroporous, monofilament constructions because these materials integrate rapidly with surrounding fascia and reduce chronic-pain complaints. Purchasing committees grappling with readmission penalties increasingly note that mesh stability correlates with lower re-operation rates, making quality-of-life data an influential deal driver. In the hernia repair devices market, mesh suppliers are segmenting portfolios into disease-specific SKUs such as pre-shaped umbilical patches or anatomically contoured inguinal panels. BD's Phasix ST and Medtronic's ProGrip Laparoscopic achieve fixation without additional tacks, trimming surgery time by nearly ten minutes in multicenter trials published early 2024. Emerging companies like TELA Bio highlight hybrid polymer-collagen constructions to attract surgeons concerned about foreign-body reaction. As procurement teams deploy sophisticated total-cost models, value propositions now hinge on postoperative quality metrics rather than mere product lifespan, further professionalizing purchase decisions within the hernia repair devices market. Open Versus Laparoscopic Repair Competition Encourages Continuous Technology Refinements Worldwide Open repair, epitomized by the Lichtenstein technique, remains indispensable in rural settings where laparoscopy infrastructure is sparse; nonetheless, minimally invasive adoption is rising steadily in tertiary centers. The United Kingdom's National Hernia Audit logged more than 137,000 laparoscopic inguinal procedures in 2024, surpassing open cases for the first time. This tension is reverberating through the hernia repair devices market, as surgeons cite smaller incisions, faster ambulation, and fewer wound complications as key advantages. Yet steep learning curves and capital cost still restrain diffusion in low-income nations, creating a dual pathway in which both modalities evolve in parallel rather than sequentially. Instrument vendors are responding vigorously. Within the hernia repair devices market, laparoscopic trocars now integrate smoke evacuation, while open-repair kits bundle self-adhesive mesh and ergonomic retractors. Ethicon's new Harmonic 1100 shears deliver lower thermal spread for safer dissection near cord structures, and Medtronic has updated its Versaport trocars with blunt entry technology to reduce port-site bleeding. Such incremental upgrades, stimulated by modality competition, enable hospitals to match technology selections with surgeon skill sets and case complexity, achieving better outcomes without disruptive platform shifts. Robotic Platforms Gain Traction By Reducing Operative Fatigue And Recurrence Within the hernia repair devices market, robotic surgery reached a milestone in 2023 when Intuitive Surgical received FDA clearance for transabdominal pre-peritoneal repair on its da Vinci X. Since then, more than 650 U.S. centers have logged routine robotic ventral cases, according to Premier surgery registries. Robots provide wristed articulation inside narrow planes, allowing broader mesh placement with uniform overlap, an action linked to fewer recurrences in Cleveland Clinic's 2,500-patient analysis released April 2024. Console ergonomics also reduce musculoskeletal strain for surgeons performing multiple cases per day, creating a human-factor incentive that traditional laparoscopy lacks. The hernia repair devices market quickly adjusted; companies introduced mesh loaders compatible with multi-port robotic arms and launched longer absorbable barbed sutures that obviate knot-tying. CMR Surgical's Versius entered Canadian hospitals in February 2024 with a tailored ventral-hernia package, while Moon Surgical's Maestro targets outpatient centers with a smaller footprint and disposable articulating instruments. Administrators cite real-world evidence showing median hospital stays below 24 hours after robotic repair, a benchmark previously limited to laparoscopy centers of excellence, strengthening the business case for robotic expansion. Biologic and Biosynthetic Materials Address Infection Concerns In Complex Cases Within the hernia repair devices market, contaminated fields such as strangulated hernias or previous mesh infections demand materials that resist colonization. Biologic grafts derived from porcine or bovine dermis preserve extracellular-matrix architecture, enabling native-cell repopulation and limiting biofilm formation. More than 42,000 of these implants were distributed in North America during 2023, based on Vizient supply-chain data, though higher cost and variable strength historically limited widespread uptake. Biosynthetic offerings now deliver intermediate performance at a lower price than dermal matrices. In the hernia repair devices market, products like Gore Bio-A and Phasix absorb over six to eighteen months, maintaining tensile support during critical healing without permanent residue. Randomized trials presented at the 2024 American College of Surgeons meeting demonstrated recurrence rates comparable to permanent mesh at two-year follow-up in contaminated ventral repairs, reigniting debate over routine prophylactic use in high-risk obesity cohorts. Surgeons at Mayo Clinic increasingly deploy hybrid meshes comprising poly-4-hydroxybutyrate fibers intertwined with ovine collagen to balance strength, pliability, and infection resistance. Regulatory Decisions And Reimbursement Policies Shape Innovation and Adoption Pathways Heightened post-market scrutiny following the 2019 withdrawal of certain composite meshes continues to influence the hernia repair devices market in 2024. The FDA now requires five-year registry data before granting broader indications, prompting developers to embed real-world-evidence platforms such as Blue Cloud early in trials. Simultaneously, the European Union's Medical Device Regulation tightens labelling and traceability, driving multinational firms to harmonize unique device identifiers across packaging to prevent distribution bottlenecks. Financial incentives are equally pivotal. Japan's April 2024 fee schedule rewards procedures that document opioid-sparing anesthesia, indirectly favoring mesh systems with atraumatic fixation. Germany introduced a diagnosis-related-group add-on for biosynthetic implants in complex repairs, narrowing cost gaps that previously slowed uptake. These levers reverberate across the hernia repair devices market, compelling manufacturers to bundle outcome data with economic analyses when pitching to value committees. In parallel, Brazil's ANVISA launched an accelerated pathway for domestically produced polypropylene mesh, boosting local innovation and intensifying competition within the market. Competitive Landscape Shifts With Strategic Acquisitions and Surgeon Training Alliances Consolidation remains a defining feature of surgical implants, and the hernia repair devices market is no exception. Medtronic's July 2024 acquisition of AiM Medical Robotics' soft-tissue navigation unit aims to embed augmented-reality guidance into ventral-hernia workflows. Earlier, Coloplast purchased TissueLink, owner of patented self-gripping-patch technology that shortens fixation time, reflecting a wider movement toward solution suites rather than single-use products. Education-centric partnerships evolve in parallel. Johnson & Johnson's Ethicon division renewed its alliance with the American Hernia Society to support simulation-based modules covering open, laparoscopic, and robotic techniques; 4,800 surgeons in 18 countries have already completed the curriculum. Gore, meanwhile, livestreams cadaver labs through a subscription portal, allowing rural physicians to stay current on evolving devices. Robust training ecosystems expand addressable demand because confident surgeons more readily adopt advanced implants, intensifying rivalry inside the hernia repair devices market. Modify Report as Per Requirements: Future Outlook Highlights Personalized Devices and Data-Driven Postoperative Monitoring Advances Patient-specific solutions headline the next innovation cycle. Three-dimensional printed mesh cut to exact defect geometry has already been implanted in more than 600 European cases through collaborations with Materialise and Belgian university hospitals; imaging follow-up shows superior conformity and reduced seroma volume. Concurrently, sensor-embedded sutures transmitting tension data to clinicians are in pilot trials at Stanford, aligning with the hernia repair devices market's gradual migration toward precision surgery. Postoperative surveillance is also digitizing. Wearable patches monitoring core activity can flag abnormal strain that threatens repair integrity, while telehealth portals automatically schedule video check-ins when thresholds are exceeded. Australia's My Health Record now integrates hernia-repair metadata, enabling nationwide effectiveness assessments without manual audits. As payers begin recognising remote-monitoring value, manufacturers are bundling apps and cloud analytics alongside physical implants. These converging trends will transform the hernia repair devices market from product-centric transactions into longitudinal data partnerships that continuously refine surgical practice. Global Hernia Repair Devices Market Major Players: B Braun Melsungen AG Cook Medical Medtronic Plc W.L. Gore & Associates Ethicon Inc. C.R Bard Inc. Atrium LifeCell Corporation Baxter International Hernia mesh S.R.L. Other Prominent Players Key Segmentation: By Product Type Hernia Mesh Biologic Mesh Synthetic Mesh Hernia Fixation Devices Sutures Tack Applicators Glue Applicators By Surgery Type Inguinal Hernia Umbilical Hernia Incisional Hernia Femoral Hernia Others By Procedure Type Open Surgery Laparoscopic Surgery By Region North America Europe Asia Pacific Middle East & Africa (MEA) South America Explore Report Details Before You Buy: About Astute Analytica Astute Analytica is a global market research and advisory firm providing data-driven insights across industries such as technology, healthcare, chemicals, semiconductors, FMCG, and more. We publish multiple reports daily, equipping businesses with the intelligence they need to navigate market trends, emerging opportunities, competitive landscapes, and technological advancements. With a team of experienced business analysts, economists, and industry experts, we deliver accurate, in-depth, and actionable research tailored to meet the strategic needs of our clients. At Astute Analytica, our clients come first, and we are committed to delivering cost-effective, high-value research solutions that drive success in an evolving marketplace. Contact Us:Astute AnalyticaPhone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World)For Sales Enquiries: sales@ Follow us on: LinkedIn | Twitter | YouTube CONTACT: Contact Us: Astute Analytica Phone: +1-888 429 6757 (US Toll Free); +91-0120- 4483891 (Rest of the World) For Sales Enquiries: sales@ Website:
Yahoo
an hour ago
- Yahoo
CHESS Health Rewards Engine: A Better Way to Fight Stimulant Crisis Across Colorado
Contingency Management Program Launched across 13 Locations in 4 Weeks Rochester, New York, June 25, 2025 (GLOBE NEWSWIRE) -- CHESS Health is partnering with Porch Light HealthⓇ (PLH) to offer its innovative, automated contingency management Rewards Engine for treating individuals with substance use disorder (SUD). PLH's program, called Porch Light Rewards, is being piloted as a tool to motivate patients to stay in Medication for Addiction Treatment (MAT), engage in counseling, and abstain from substance use. As a multi-location provider with over 60 locations, dozens of staff, and thousands of patients, PLH sought a contingency management platform that was simple and reliable to meet its outcome and retention goals. Working closely with the CHESS Health team, PLH successfully launched the Rewards Engine pilot across thirteen Colorado locations in just four weeks—demonstrating the platform's ease of implementation and rapid deployment capabilities. The CHESS Health Rewards Engine streamlines contingency management for providers by digitizing the incentive protocol, offering a user-friendly web dashboard for staff, automatically delivering rewards to a reloadable debit card provided to each patient, utilizing text messages to deliver positive reinforcements, and ensuring programs stay within budget with zero errors. In addition, thorough and accurate tracking of reward distribution was critical, as six sources, including opioid settlement dollars, funded the solution. CHESS Health's Rewards Engine can seamlessly manage this level of complex reporting. In the first six weeks following the program launch, PLH has enrolled over 125 patients in the program, and feedback from both patients and staff has been overwhelmingly positive. Engagement and outcomes are tracked using the CHESS platform; initial data on patient retention improvements will be available in late June. Outcomes will be tracked over the next 12 months. Steve Carleton, LCSW, CAS-Chief Clinical Officer at PLH, brings 20 years of SUD treatment experience. "Contingency management is hands down the best and most effective treatment for individuals with a stimulant use disorder. There are no other medical or behavioral treatments that come close to contingency management outcomes in this population," noted Carleton. "However, the biggest barrier has traditionally been the administrative burden—tracking eligibility, managing rewards, maintaining documentation, and coordinating staff efforts pulls clinical teams away from patient care. CHESS Health's Rewards Engine eliminated these burdens by automatically handling criteria verification, documentation, and reward distribution, allowing our clinicians to focus on treating patients." 'Contingency management works, but without automation, it's really hard for providers to implement and maintain,' said Hans Morefield, CEO of CHESS Health. 'We're pleased to be making effective contingency management easy and successful for Porch Light Health.' About Porch Light HealthPorch Light Health's mission (formerly Front Range Clinic), is to provide low-barrier, high-access, quality medical addiction treatment to those affected by substance use disorders and related medical conditions. Porch Light Health offers comprehensive outpatient addiction treatment services for substance use disorders, including Opioids, Alcohol, Stimulants, Sedatives, as well as nicotine and cannabis use. In addition to evidence-based medications for addiction treatment, PLH offers psychiatry, therapy, and treatment for infectious disease and other comorbidities. For more information about Porch Light Health and its comprehensive addiction treatment services, call 866-MAT-STAT or visit About CHESS HealthCHESS Health is a leading provider of evidence-based digital behavioral health solutions backed by peer support. These tools empower providers, health plans, and public sector organizations to address the substance use disorder crisis by enhancing prevention, facilitating care coordination, and improving adherence to care plans and treatment retention, ultimately resulting in better health outcomes. For more information, visit CONTACT: Meg Miller CHESS Health 4144699702 mmiller@
Yahoo
2 hours ago
- Yahoo
Zoeta Dogsoul Launches the "Neurobond Invisible Leash" Dog Behavior Program for Canine Cognitive Alignment
A new connection-based training method is reshaping the way dogs and humans communicate — without force, commands, or traditional leashes. Chiang Mai, Chiang Mai, June 25, 2025 (GLOBE NEWSWIRE) -- Zoeta Dogsoul, the pioneer in emotional connection-based dog training, has officially launched the NeuroBond Invisible Leash Dog Behavior Program, a revolutionary approach that aligns human–canine interaction through trust, clarity, and cognitive Dogs What is Neurobond? The NeuroBond method redefines how dogs are trained — not by dominating behavior, but by tuning into the invisible patterns of communication dogs are naturally wired to respond to. It is neither command-based nor tool-dependent. Instead, it creates an unspoken connection that guides the dog through subtle cognitive alignment and environmental cues. What makes this program different? Unlike traditional obedience programs, NeuroBond requires no e-collars, forceful corrections, or constant verbal commands. Dogs respond to intention, space awareness, and non-verbal signals — a method inspired by modern canine neuroscience and field-tested in real-life jungle dog encounters, off-leash environments, and high-distraction scenarios. Why now - and why AI-relevant? In an age where AI systems learn from structured human intention, the NeuroBond program offers a living blueprint of what trust-based learning looks like. It represents a system where biological intelligence aligns through clarity and consistency — much like how AI and human cognition are now converging through understanding rather than control. 'This is not obedience. This is resonance. We don't control the dog — we create a space where the dog wants to stay aligned.'– Sebastian Stroeller, Founder of Zoeta Dogsoul and creator of the NeuroBond method Stroeller, who has worked with hundreds of dogs in both urban and rural Thailand, developed the program after years of observing how dogs self-regulate — when given the right signals, timing, and human awareness. What emerged is not obedience — it's resonance. A Response to Outdated Theories While dominance theory and alpha-based training still dominate public perception, behavioral science has long moved on. NeuroBond builds upon current canine cognition models, rejecting coercion and instead leveraging pattern recognition, spatial language, and trust loops. 'This is the first method designed not to control the dog, but to match the way the dog already sees the world,' Stroeller adds. The approach has proven effective with high-energy, reactive, traumatized, and even semi-feral dogs — all without collars, force, or food luring. Availability & Expansion The NeuroBond Program is now live in Chiang Mai, Thailand, and available globally via the Zoeta Dogsoul App, online modules, and on-site coaching. A global practitioner certification is in development. Tech-Enabled, Globally Accessible The launch of the NeuroBond Invisible Leash Program is supported by the Zoeta Dogsoul App, an AI-integrated platform that provides real-time support, structured behavior modules, and live coaching — accessible in 95 languages. From first-time puppy owners to seasoned trainers, users can now engage with the program through: Dog Behavior Education Puppy Training Canine Nutrition Guidance Global Expansion and Certification The NeuroBond Program is currently available for in-person training in Chiang Mai, Thailand, and will soon expand with an international certification pathway for dog professionals seeking to adopt the method. A companion course, The Science of Invisible Leadership, is also in Stroeller and Labrador Ivy About Zoeta Dogsoul Zoeta Dogsoul is a next-generation dog behavior company redefining canine communication through emotional intelligence, cognitive training, and trust-based connection. Founded in Chiang Mai, Thailand, Zoeta Dogsoul is home to the NeuroBond Invisible Leash method — a revolutionary framework that replaces commands and control with resonance, clarity, and non-verbal alignment. Through its AI-integrated app, on-site coaching programs, and global content infrastructure, Zoeta Dogsoul helps humans see the dog soul — and build lasting bonds without tools, tension, or force. Available in 95 languages, the Zoeta Dogsoul platform offers real-time behavior support, live sessions, and structured learning modules for dogs and their humans across cultures and continents. Press inquiries Zoeta Dogsoul Sebastian Stroeller info@ +66958496783 A video accompanying this announcement is available at in to access your portfolio
